Hyperfine, Inc. (HYPR)
NASDAQ: HYPR · Real-Time Price · USD
0.6970
-0.0193 (-2.69%)
Apr 1, 2025, 10:26 AM EDT - Market open
Hyperfine Revenue
In the year 2024, Hyperfine had annual revenue of $12.89M with 16.84% growth. Hyperfine had revenue of $2.32M in the quarter ending December 31, 2024, a decrease of -13.59%.
Revenue (ttm)
$12.89M
Revenue Growth
+16.84%
P/S Ratio
4.02
Revenue / Employee
$116,126
Employees
111
Market Cap
54.25M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
HYPR News
- 14 days ago - Hyperfine, Inc. (HYPR) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 14 days ago - Hyperfine, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 14 days ago - Hyperfine, Nvidia Partner To Make Brain MRIs More Affordable - Benzinga
- 27 days ago - Hyperfine, Inc. to Announce Fourth Quarter and Full Year 2024 Financial Results on March 17, 2025 - Business Wire
- 7 weeks ago - Hyperfine Announces $6.0 Million Registered Direct Offering - Business Wire
- 7 weeks ago - Hyperfine Reports on Growing Evidence for the Use of Swoop® System Images in Stroke Diagnosis Presented at the 2025 International Stroke Conference - Business Wire
- 3 months ago - Hyperfine Expands Global Market Reach with New Distribution Partnerships in European and Middle Eastern Markets - Business Wire
- 4 months ago - Hyperfine Announces Extensive Clinical Study Coverage at RSNA 2024, Showcasing the Body of Evidence Supporting the Use of the Swoop® System Across Different Sites of Care - Business Wire